Objective To explore the efficacy of anlotinib combined with docetaxel in patients with non-small cell lung cancer(NSCLC)having failure of chemotherapy of tyrosine kinase inhibitor combined with platinum.Methods A total of 83 patients with NSCLC who failed to receive tyrosine kinase inhibitor combined with platinum chemotherapy in our hospital from June 2021 to May 2022 were selected as the subjects in this study.The 83 patients were randomized into the control group(n=41)and observation group(n=42).The patients in the control group were treated with anlotinib and those in the observation one with the combination of allotinib and docetaxel.The efficacy,vascular endothelial growth factor(VEGF),matrix metalloproteinase 9(MMP9)before and after treatment and adverse reactions were compared between the 2 groups.Results The total effective rate was significantly lower in the control group in the observation one(68.29%vs 88.10%,P<0.05).VEGF and MMP9 levels in the observation group were significantly improved as compared with the control[(82.34±11.45) pg·mL-1 vs(114.67±11.57) pg·mL-1,(82.46±7.26) ng·mL-1 vs(132.18±7.12) ng·mL-1,t=12.795,31.493,P<0.05].There was no statistical difference in occurrence of adverse reactions between the 2 groups(23.81%vs 12.20%)(χ2=1.890,P>0.05).Conclusion Anlotinib combined with docetaxel can improve the therapeutic effect and reduce serum VEGF and MMP9 levels in NSCLC patients who have failure in chemotherapy of tyrosine kinase inhibitor combined with platinum.
NETL
NSTL
万方数据
